Skip to main content
SpringerLink
Log in

The Use of Transcranial Magnetic Stimulation in the Treatment of Depressive Disorder in Parkinson’s Disease

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

The prevalence of affective disorders in patients with Parkinson’s disease (PD) is significantly higher than that in the general population of people of the same age. The efficacy of antidepressants in PD with depressive disorder is known to be lower than in patients with primary depression. Other therapeutic strategies are available in cases of depression refractory to standard pharmacotherapy. Transcranial magnetic stimulation is one of the most popular and safe methods of brain stimulation and has been used with success to treat primary depression. The accumulation of experience in the use of transcranial magnetic stimulation has allowed the application of this method to be expanded to other nosologies, including PD. This article reflects published data on the use of different transcranial magnetic stimulation protocols for the treatment of depressive disorder in patients with PD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. O. Tysnes and A. Storstein, “Epidemiology of Parkinson’s disease,” J. Neural Transm. (Vienna), 124, No. 8, 901–905 (2017), https://doi.org/10.1007/s00702-017-1686-y.

    Article  PubMed  Google Scholar 

  2. J. Parkinson, An Essay on Shaking Palsy, Sherwood, Neeley, and Jones, London (1817).

    Google Scholar 

  3. R. Randver, “Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex to alleviate depression and cognitive impairment associated with Parkinson’s disease: A review and clinical implications,” J. Neurol. Sci., 393, 88–99 (2018), https://doi.org/10.1016/j.jns.2018.08.014.

    Article  PubMed  Google Scholar 

  4. S. von Campenhausen, B. Bornschein, R. Wick, et al., “Prevalence and incidence of Parkinson’s disease in Europe,” Eur. Neuropsychopharmacol., 15, No. 4, 473–490 (2005), https://doi.org/10.1016/j.euroneuro.2005.04.007.

    Article  CAS  Google Scholar 

  5. M. C. de Rijk, M. M. Breteler, G. A. Graveland, et al., “Prevalence of Parkinson’s disease in the elderly: The Rotterdam Study,” Neurology, 45, No. 12, 2143–2146 (1995), https://doi.org/10.1212/wnl.45.12.2143.

  6. L. M. de Lau and M. M. Breteler, “Epidemiology of Parkinson’s disease,” Lancet Neurol., 5, No. 6, 525–535 (2006), https://doi.org/10.1016/s1474-4422(06)70471-9.

    Article  PubMed  Google Scholar 

  7. D. K. Simon, C. M. Tanner, and P. Brundin, “Parkinson disease epidemiology, pathology, genetics, and pathophysiology,” Clin. Geriatr. Med., 36, No. 1, 1–12 (2020), https://doi.org/10.1016/j.cger.2019.08.002.

    Article  PubMed  Google Scholar 

  8. V. W. Sung and A. P. Nicholas, “ Nonmotor symptoms in Parkinson’s disease: Expanding the view of Parkinson’s disease beyond a pure motor, pure dopaminergic problem,” Neurol. Clin., 31, No. 3, S1–S16 (2013), https://doi.org/10.1016/j.ncl.2013.04.013.

    Article  PubMed  Google Scholar 

  9. K. R. Chaudhuri, L. Yates, and P. Martinez-Martin, “The non-motor symptom complex of Parkinson’s disease: A comprehensive assessment is essential,” Curr. Neurol. Neurosci. Rep., 5, No. 4, 275–283 (2005), https://doi.org/10.1007/s11910-005-0072-6.

    Article  PubMed  Google Scholar 

  10. L. M. Shulman, R. L. Taback, J. Bean, and W. J. Weiner, “Comorbidity of the nonmotor symptoms of Parkinson’s disease,” Mov. Disord., 16, No. 3, 507–510 (2001), https://doi.org/10.1002/mds.1099.

    Article  CAS  PubMed  Google Scholar 

  11. T. Simuni and K. Sethi, “Nonmotor manifestations of Parkinson’s disease,” Ann. Neurol., 64, S2, 65–80 (2008), https://doi.org/10.1002/ana.21472.

    Article  Google Scholar 

  12. T. Witjas, E. Kaphan, J. P. Azulay, et al., “Nonmotor fluctuations in Parkinson’s disease: frequent and disabling,” Neurology, 59, No. 3, 408–413 (2002), https://doi.org/10.1212/wnl.59.3.408.

  13. T. Ziemssen and H. Reichmann, “Non-motor dysfunction in Parkinson’s disease,” Parkinsonism Relat. Disord., 13, No. 6, 323–332 (2007), https://doi.org/10.1016/j.parkreldis.2006.12.014.

    Article  PubMed  Google Scholar 

  14. P. Martinez-Martin, C. Rodriguez-Blazquez, M. M. Kurtis, et al., “The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease,” Mov. Disord., 26, No. 3, 399–406 (2011), https://doi.org/10.1002/mds.23462.

    Article  PubMed  Google Scholar 

  15. N. Hwynn, I. U. Haq, I. A. Malaty, et al., “The frequency of nonmotor symptoms among advanced Parkinson patients may depend on instrument used for assessment,” Parkinsons Dis., 2011, 1–4 (2011), https://doi.org/10.4061/2011/290195.

    Article  Google Scholar 

  16. D. A. Gallagher and A. Schrag, “Psychosis, apathy, depression and anxiety in Parkinson’s disease,” Neurobiol. Dis., 46, No. 3, 581–589 (2012), https://doi.org/10.1016/j.nbd.2011.12.041.

    Article  PubMed  Google Scholar 

  17. M. R. Lemke, G. Fuchs, I. Gemende, et al., “Depression and Parkinson’s disease,” J. Neurol., 251, No. 6, vi24–vi27 (2004), 10.1007/s00415-004-1606-6.

  18. D. D. Truong, R. Bhidayasiri, and E. Wolters, “Management of non-motor symptoms in advanced Parkinson disease,” J. Neurol. Sci., 266, No. 1–2, 216–228 (2008), https://doi.org/10.1016/j.jns.2007.08.015.

    Article  PubMed  Google Scholar 

  19. A. Schrag and R. N. Taddei, “Depression and anxiety in Parkinson’s disease,” Int. Rev. Neurobiol., 133, 623–655 (2017), https://doi.org/10.1016/bs.irn.2017.05.024.

    Article  PubMed  Google Scholar 

  20. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Publishing (2013), 5th ed., https://doi.org/10.1176/appi.books.9780890425596.

  21. J. S. A. M. Reijnders, U. Ehrt, W. E. J. Weber, et al., “A systematic review of prevalence studies of depression in Parkinson’s disease,” Mov. Disord., 23, No. 2, 183–189 (2008), https://doi.org/10.1002/mds.21803.

    Article  PubMed  Google Scholar 

  22. B. Liu, Y. Zhang, L. Zhang, and L. Li, “Repetitive transcranial magnetic stimulation as an augmentative strategy for treatment-resistant depression, a meta-analysis of randomized, double-blind and sham-controlled study,” BMC Psychiatry, 14, No. 1, 1–9 (2014), https://doi.org/10.1186/s12888-014-0342-4.

  23. A. Fagiolini and D. J. Kupfer, “Is treatment-resistant depression a unique subtype of depression?” Biol. Psychiatry, 53, No. 8, 640–648 (2003), https://doi.org/10.1016/s0006-3223(02)01670-0.

    Article  PubMed  Google Scholar 

  24. A. J. Ferrari, A. J. Somerville, A. J. Baxter, et al., “Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature,” Psychol. Med., 43, No. 3, 471–481 (2013), https://doi.org/10.1017/s0033291712001511.

    Article  CAS  PubMed  Google Scholar 

  25. M. S. George, J. J. Taylor, and E. B. Short, “The expanding evidence base for rTMS treatment of depression,” Curr. Opin. Psychiatry, 26, No. 1, 13–18 (2013), https://doi.org/10.1097/yco.0b013e32835ab46d.

    Article  PubMed  PubMed Central  Google Scholar 

  26. A. R. Brunoni, A. Chaimani, A. H. Moffa, et al., “Repetitive transcranial magnetic stimulation for the acute treatment of major depressive episodes: A systematic review with network meta-analysis,” JAMA Psychiatry, 74, No. 2, 143 (2017), https://doi.org/10.1001/jamapsychiatry.2016.3644.

  27. P. Fitzgerald, S. Fountain, and Z. Daskalakis, “A comprehensive review of the effects of rTMS on motor cortical excitability and inhibition,” Clin. Neurophysiol., 117, No. 12, 2584–2596 (2006), https://doi.org/10.1016/j.clinph.2006.06.712.

    Article  PubMed  Google Scholar 

  28. H. S. Mayberg, S. K. Brannan, J. L. Tekell, et al., “Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response,” Biol. Psychiatry, 48, No. 8, 830–843 (2000), https://doi.org/10.1016/s0006-3223(00)01036-2.

    Article  CAS  PubMed  Google Scholar 

  29. N. Kamble, M. Netravathi, and P. K. Pal, “Therapeutic applications of repetitive transcranial magnetic stimulation (rTMS) in movement disorders: a review,” Parkinsonism Relat. Disord., 20, No. 7, 695–707 (2014), https://doi.org/10.1016/j.parkreldis.2014.03.018.

    Article  PubMed  Google Scholar 

  30. C. Xie, J. Chen, X. Wang, et al., “Repetitive transcranial magnetic stimulation (rTMS) for the treatment of depression in Parkinson disease: a meta-analysis of randomized controlled clinical trials,” Neurol. Sci., 36, No. 10, 1751–1761 (2015), https://doi.org/10.1007/s10072-015-2345-4.

    Article  PubMed  Google Scholar 

  31. K. Machii, D. Cohen, C. Ramos-Estebanez, and A. Pascual-Leone, “Safety of rTMS to non-motor cortical areas in healthy participants and patients,” Clin. Neurophysiol., 117, No. 2, 455–471 (2006), https://doi.org/10.1016/j.clinph.2005.10.014.

    Article  PubMed  Google Scholar 

  32. N. Dragaševic, A. Potrebić, et al., “Therapeutic efficacy of bilateral prefrontal slow repetitive transcranial magnetic stimulation in depressed patients with Parkinson’s disease: an open study,” Mov. Disord., 17, No. 3, 528–532 (2002), https://doi.org/10.1002/mds.10109.

    Article  PubMed  Google Scholar 

  33. F. Fregni, C. M. Santos, M. L. Myczkowski, et al., “Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson’s disease,” J. Neurol. Neurosurg. Psychiatry, 75, No. 8, 1171–1174 (2004), https://doi.org/10.1136/jnnp.2003.027060.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. C. M. Epstein, M. L. Evatt, A. Funk, et al., “An open study of repetitive transcranial magnetic stimulation in treatment-resistant depression with Parkinson’s disease,” Clin. Neurophysiol., 118, No. 10, 2189–2194 (2007), https://doi.org/10.1016/j.clinph.2007.07.010.

    Article  PubMed  PubMed Central  Google Scholar 

  35. E. Pal, F. Nagy, Z. Aschermann, et al., “The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson’s disease: a randomized, double-blind, placebo-controlled study,” Mov. Disord., 25, No. 14, 2311–2317 (2010), https://doi.org/10.1002/mds.23270.

    Article  PubMed  Google Scholar 

  36. J. Lefaucheur, N. Andre-Obadia, A. Antal, et al., “Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS),” Clin. Neurophysiol., 125, No. 11, 2150–2206 (2014), https://doi.org/10.1016/j.clinph.2014.05.021.

    Article  PubMed  Google Scholar 

  37. M. Brys, M. D. Fox, S. Agarwal, et al., “Multifocal repetitive TMS for motor and mood symptoms of Parkinson disease: a randomized trial,” Neurology, 87, No. 18, 1907–1915 (2016), https://doi.org/10.1212/wnl.0000000000003279.

  38. J. Lefaucheur, A. Aleman, C. Baeken, et al., “Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS), An update (2014–2018),” Clin. Neurophysiol., 131, No. 2, 474–528 (2020), https://doi.org/10.1016/j.clinph.2019.11.002.

    Article  PubMed  Google Scholar 

  39. A. M. Lesenskyj, M. P. Samples, J. M. Farmer, and C. R. Maxwell, “Treating refractory depression in Parkinson’s disease: a meta-analysis of transcranial magnetic stimulation,” Transl. Neurodegener., 7, No. 1, 1–6 (2018), https://doi.org/10.1186/s40035-018-0113-0.

    Article  CAS  Google Scholar 

  40. W. Hai-Jiao, T. Ge, Z. Li-Na, et al., “The efficacy of repetitive transcranial magnetic stimulation for Parkinson disease patients with depression,” Int. J. Neurosci., 130, No. 1, 19–27 (2020), https://doi.org/10.1080/00207454.2018.1495632.

    Article  CAS  PubMed  Google Scholar 

  41. H. Shin, Y. C. Youn, S. J. Chung, and Y. H. Sohn, “Effect of high-frequency repetitive transcranial magnetic stimulation on major depressive disorder in patients with Parkinson’s disease,” J. Neurol., 263, No. 7, 1442–1448 (2016), https://doi.org/10.1007/s00415-016-8160-x.

    Article  CAS  PubMed  Google Scholar 

  42. S. Li, R. Jiao, X. Zhou, and S. Chen, “Motor recovery and antidepressant effects of repetitive transcranial magnetic stimulation on Parkinson disease: A PRISMA-compliant meta-analysis,” Medicine (Baltimore), 99, No. 18, e19642 (2020), https://doi.org/10.1097/MD.0000000000019642.

  43. M. VonLoh, R. Chen, and B. Kluger, “Safety of transcranial magnetic stimulation in Parkinson’s disease: a review of the literature,” Parkinsonism Relat. Disord., 19, No. 6, 573–585 (2013), https://doi.org/10.1016/j.parkreldis.2013.01.007.

    Article  PubMed  PubMed Central  Google Scholar 

  44. S. Rossi, M. Hallett, P. M. Rossini, and A. Pascual-Leone, “Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research,” Clin. Neurophysiol., 120, No. 12, 2008–2039 (2009), https://doi.org/10.1016/j.clinph.2009.08.016.

    Article  PubMed  PubMed Central  Google Scholar 

  45. D. H. Benninger, B. D. Berman, E. Houdayer, et al., “Intermittent theta-burst transcranial magnetic stimulation for treatment of Parkinson disease,” Neurology, 76, No. 7, 601–609 (2011), https://doi.org/10.1212/WNL.0b013e31820ce6bb.

  46. F. Torres, E. Villalon, P. Poblete, et al., “Retrospective evaluation of deep transcranial magnetic stimulation as add-on treatment for Parkinson’s disease,” Front. Neurol., 6, 210 (2015), https://doi.org/10.3389/fneur.2015.00210.

    Article  PubMed  PubMed Central  Google Scholar 

  47. K. Seppi, K. R. Chaudhuri, M. Coelho, et al., “Update on treatments for nonmotor symptoms of Parkinson’s disease – an evidence-based medicine review,” Mov. Disord., 34, No. 2, 180–198 (2019), https://doi.org/10.1002/mds.27602.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Evdokimov Moscow State Medical and Dental University, Russian Ministry of Health, Moscow, Russia

    A. O. Prosvetov, B. D. Tsygankov, E. V. Kuznetsov & S. R. Rangus

  2. Solov’ev Scientific and Applied Psychoneurology Center, Moscow Health Department, Moscow, Russia

    A. B. Guekht, U. E. Less, D. A. Tumurov & G. R. Popov

  3. Institute of Metal Health and Addiction Medicine, Moscow, Russia

    D. B. Tsygankov

Authors
  1. A. O. Prosvetov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. D. Tsygankov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. B. Guekht
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. V. Kuznetsov
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. U. E. Less
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. A. Tumurov
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. R. Popov
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D. B. Tsygankov
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S. R. Rangus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. O. Prosvetov.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 122, No. 9, pp. 79–85, September, 2022.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Prosvetov, A.O., Tsygankov, B.D., Guekht, A.B. et al. The Use of Transcranial Magnetic Stimulation in the Treatment of Depressive Disorder in Parkinson’s Disease. Neurosci Behav Physi 53, 517–523 (2023). https://doi.org/10.1007/s11055-023-01450-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-023-01450-4

Keywords

Search

Navigation